Neural Mechanisms of Response Inhibition Training for OCRD

Obsessive-Compulsive Disorder Clinical Trial

— OCRD  

Official title:

Neural Mechanisms of Response Inhibition Training for Obsessive-Compulsive Disorder and Related Conditions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05377125
• Other study ID #: PRO00042324
• Status: Recruiting
• Phase: N/A
• Start date: December 22, 2022
• Est. completion date: August 2027

Study information

• Verified date: April 2024
• Source: University of Wisconsin, Milwaukee
• Contact: Hanjoo Lee, Ph.D.
• Phone: 414-229-5858
• Email: leehj[@]uwm.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The impaired ability to suppress an inappropriate but pre-potent response (response inhibition; RI) characterizes several debilitating clinical problems, including obsessive-compulsive and related disorders (OCRD) such as obsessive-compulsive disorder, trichotillomania, and skin picking disorder. There is a critical need to develop an effective and durable treatment for OCRDs with demonstrable evidence for improving impaired RI. The purpose of our project is to examine the impact of a novel computerized intervention, response inhibition training (RIT), on neural indices of RI, and examine the mechanistic link between engagement of the neural RI targets and change in OCRD symptoms. To this end, this project will conduct a randomized clinical trial for individuals with OCD, trichotillomania, and/or skin picking disorders. Participants will be randomly assigned to 8 to 16 sessions of computerized RIT or a computerized placebo training. Various clinical, behavioral, and brain-imaging data will be acquired to evaluate the training effects at baseline, post-training, and 1-month follow-up periods.

Description:

Research has documented abnormal inhibition-related brain activity as well as impaired behavioral performance of RI in OCRD. Despite the growing evidence suggesting a RI deficit as a fundamental process in OCRD, no validated treatment exists that can directly alter RI deficits and in turn ameliorate OCRD symptoms. It is vital to develop a highly specific intervention that precisely engages a theoretically and empirically well-grounded target such as RI deficits, to significantly improve the efficacy of our intervention efforts. The overarching goal of this study is to examine whether the computerized cognitive training program can improve the neural indicators of the ability to inhibit inappropriate responses, and produce a clinically meaningful level of reduction in obsessive-compulsive disorder and related symptoms. Our central hypothesis is that cognitive training designed to enhance RI will improve neural indices: fronto-basal ganglia circuitry, especially right inferior frontal cortex of RI among individuals with OCRDs. We also hypothesize that the change in the RI neural circuit will mediate the consequent clinical improvements in OCRD symptomatology. Phase I (R61) will aim to examine change in neural RI indices via the RIT intervention, Adults diagnosed with OCRD problems (OCD, TTM, or SPD) will be randomly assigned to the RIT or placebo control (PLT) condition. At pre- and post-training, neurobehavioral measures of RI will be taken, including the Stop-Signal Task (SST) assessing SSRT and fMRI task assessing rIFC activation. Each RIT participant will continue with the training within the range of 8 to 16 sessions until the criterion-level change in SSRT is attained (based on the ongoing SSRT estimation), with the PLT group receiving comparable levels of training. We will also collect 1-month follow-up data on functional outcomes in order to obtain information on the effect of the intervention on the OCRD symptom indices. Phase II (R33) is identical to Phase I in the overall study procedures. Adults diagnosed with OCRD problems will be assigned to RIT or PLT. Analytic focus will be on the reduction in OCRD symptoms and their potential mediational pathway (rather than the change in the neural RI indices, which is the primary analytic focus in Phase I). Other than these differences, the overall flow and procedures of the study will be identical between Phases I and II. The key assessments will include the fMRI tasks of the RI processes and clinician-administered measures of OCRD symptoms. There are other self-reported, computerized, and clinician-administered measures that will be administered across various points over the course of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 118
• Est. completion date: August 2027
• Est. primary completion date: July 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• age between 18 and 60
• moderate level of OCRD symptoms (Yale-Brown Obsessive Compulsive Scale total = 16, Massachusetts General Hospital-Hair pulling Scale total = 12, or Skin Picking Scale-Revised total = 7)
• a primary diagnosis of OCRD (i.e., OCD, TTM, or SPD)
• estimated IQ > 80
• presence of a RI deficits (SSRT = 215ms).

Exclusion Criteria:

• Current substance use disorder
• Severe ADHD
• Lifetime diagnosis of psychotic disorder, bipolar disorder, or schizophrenia
• Current psychotherapy
• Change in psychotropic medication status within 8 weeks before the study or during the study
• Use of stimulant medication
• Active suicidal risk
• Contraindications for MRI procedures

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder
• Skin-Picking

Intervention

Behavioral:
• Computerized cognitive training
This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
• Computerized placebo training
This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.

Locations

Country	Name	City	State
United States	UWM Anxiety Disorders Laboratory	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Milwaukee

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in obsessive-compulsive disorder symptom severity over time	Depending on participant's primary diagnostic condition, Yale-Brown Obsessive Compulsive Scale (YBOCS) will be used as the primary outcome measure for assessing the change in OCD symptoms over time.; The total score ranges between 0 and 40 with higher scores indicating worse outcomes (= more severe symptoms).	Week 0, Week 4, Week 8 ~ 12
Primary	Change in compulsive hair pulling symptom severity over time	Depending on participant's primary diagnostic condition, National Institute of Mental Health - Trichotillomania Symptom Severity Scale (NIMH-TSS) will be used as the primary outcome measure for assessing the change in hair pulling symptoms over time.; The total score ranges between 0 and 25 with higher scores indicating worse outcomes (= more severe symptoms).	Week 0, Week 4, Week 8 ~ 12
Primary	Change in compulsive skin picking symptom severity over time	Depending on participant's primary diagnostic condition, Yale-Brown Obsessive Compulsive Scale modified for Neurotic Excoriation (NE-YBOCS) will be used as the primary outcome measure for assessing the change in skin picking symptoms over time.; The total score ranges between 0 and 40 with higher scores indicating worse outcomes (= more severe symptoms).	Week 0, Week 4, Week 8 ~ 12
Primary	Change in activation in the right inferior frontal cortex (rIFC)	Change in the level of blood-oxygen-level-dependent (BOLD) signal activation in the right inferior frontal cortex (rIFC) will be assessed using the stop-signal task (SST) that will be administered while the participant undergoes a functional magnetic resonance imaging procedure.	Week 0, Week 4
Secondary	Change in the Clinical Global Impression Scale	The Clinical Global Impression Scale (CGI-I) is a clinician-administered rating scale on the overall improvement of the participant's condition throughout treatment.; The rating score ranges between 1 and 8 with higher scores indicating worse outcomes (= more severe symptoms).	Week 0, Week 4, Week 8 ~ 12